Please login to the form below

Not currently logged in
Email:
Password:

Caprelsa

This page shows the latest Caprelsa news and features for those working in and with pharma, biotech and healthcare.

Home-grown colorectal cancer drug approved in China

Home-grown colorectal cancer drug approved in China

Meanwhile, other orally-active drugs that target VEGF – including Bayer’s Nexavar (sorafenib), Novartis’Votrient (pazopanib), and Sanofi’s Caprelsa (vandetanib) – have been developed for a range of other solid tumours

Latest news

  • AZ sells rare cancer drug to Sanofi AZ sells rare cancer drug to Sanofi

    Sanofi's rare diseases unit Genzyme will pay AstraZeneca up to $300 million for the global rights to the firm's rare disease drug Caprelsa (vandetanib). ... Caprelsa is not however a blockbuster drug and saw sales of just $48m last year.

  • Eisai’s thyroid cancer drug Lenvima nears EU approval Eisai’s thyroid cancer drug Lenvima nears EU approval

    AstraZeneca also has a thyroid cancer drug in the form of Caprelsa(vandetanib), although this has a different licence, namely for the treatment of aggressive and symptomatic medullary thyroid cancer in

  • Eisai given early approval for new oncology drug Eisai given early approval for new oncology drug

    In 2012 the EMA gave the green light to AstraZeneca's Caprelsa (vandetanib), although this is for a different form of the disease, specifically for the treatment of aggressive and symptomatic

  • FDA approves Exelixis’ Cometriq for rare thyroid cancer FDA approves Exelixis’ Cometriq for rare thyroid cancer

    The approval follows a similar recommendation for AstraZeneca's Caprelsa (vandetanib) last year, with both drugs now available for use in this limited population. ... Prior to today's approval and the approval of Caprelsa in April 2011, patients with

  • AstraZeneca wins European approval for thyroid cancer drug Caprelsa

    The European Commission has approved AstraZeneca's Caprelsa making it the first licensed treatment for advanced medullary thyroid cancer (MTC) in Europe. ... Analysts at Reuters said they expect worldwide sales of Caprelsa to peak at around $128m in

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    Firstly the divestment for up to $300m to Genzyme of Caprelsa (vandetanib), an orphan drug treatment for thyroid carcinoma. ... 560+. AstraZeneca / Genzyme. Acquisition of R&D. Caprelsa (vandetanib) marketed. 300.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and Iressa (gefitinib), an epidermal growth factor receptor tyrosine kinase

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics